Literature DB >> 17596539

How I treat acute lymphocytic leukemia in adults.

Jacob M Rowe1, Anthony H Goldstone.   

Abstract

The treatment of newly diagnosed acute lymphocytic leukemia (ALL) in adults remains unsatisfactory. Not withstanding the outstanding progress in curing childhood ALL, only approximately one third of adults younger than 60 years can be cured, and the overall published survival curves have not changed significantly during the past 15 years. Recent therapeutic advances in allogeneic transplantation through the conduct of large collaborative studies, better understanding of the relevance of cytogenetics, improved molecular techniques for the detection of minimal residual disease, and clinical research into novel biologic and targeted therapies have all combined to offer potentially a better hope for an improved outcome in this disease. The current approach in 2007 to the management of this disease is presented by way of a discussion of illustrative cases. In this uncommon and difficult disease, well-structured intergroup studies will remain vital for future progress.

Entities:  

Mesh:

Year:  2007        PMID: 17596539     DOI: 10.1182/blood-2007-05-038950

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Inhibition of tumor necrosis factor-α enhances apoptosis induced by nuclear factor-κB inhibition in leukemia cells.

Authors:  Qiao-Mei Dong; Chun Ling; Xuan Chen; L I Zhao
Journal:  Oncol Lett       Date:  2015-10-08       Impact factor: 2.967

2.  The Austrian Bone Marrow Donor Registry: Providing Patients in Austria with Unrelated Donors for Transplant - a Worldwide Cooperation.

Authors:  Agathe Rosenmayr; Margit Pointner-Prager; Martina Winkler; Andrea Mitterschiffthaler; Barbara Pelzmann; Ljiljana Bozic; Sonja-Kurzweil Pichler; Heinz Tüchler; Ingrid Fae; Gottfried Fischer
Journal:  Transfus Med Hemother       Date:  2011-09-22       Impact factor: 3.747

3.  Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

Authors:  Anthony S Stein; Joycelynne M Palmer; Margaret R O'Donnell; Neil M Kogut; Ricardo T Spielberger; Marilyn L Slovak; Ni-Chun Tsai; David Senitzer; David S Snyder; Sandra H Thomas; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-11       Impact factor: 5.742

4.  Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Authors:  Shuhua Zheng; Gilles M Leclerc; Bin Li; Ronan T Swords; Julio C Barredo
Journal:  Oncotarget       Date:  2017-12-31

Review 5.  Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.

Authors:  Jing-Zhou Hou; Jing Christine Ye; Jeffrey J Pu; Hongtao Liu; Wei Ding; Hong Zheng; Delong Liu
Journal:  J Hematol Oncol       Date:  2021-04-21       Impact factor: 17.388

Review 6.  Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Authors:  Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

7.  Kidney and pancreatic extramedullary relapse in adult acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Leslie Skeith; Alejandro Lazo-Langner; Joy Mangel
Journal:  Case Rep Hematol       Date:  2013-08-01

8.  Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.

Authors:  Deborah Saltman; Arie Barlev; Divyagiri Seshagiri; Ioannis Katsoulis; Vincent Lin; Beth Barber
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

9.  Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.

Authors:  Katherine Linder; Deepthi Gandhiraj; Madhura Hanmantgad; Karen Seiter; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2016-07-26

10.  Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.

Authors:  Winfried H Alsdorf; Panagiotis Karagiannis; Claudia Langebrake; Carsten Bokemeyer; Christian Frenzel
Journal:  Oncologist       Date:  2020-11-28       Impact factor: 5.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.